Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
-
REGULATORY Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
-
BUSINESS Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
-
BUSINESS Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
-
BUSINESS Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
-
BUSINESS Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
-
BUSINESS Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
-
BUSINESS Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
-
BUSINESS Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
-
ORGANIZATION Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
-
BUSINESS Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
-
REGULATORY MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
-
BUSINESS 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
-
BUSINESS Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
-
REGULATORY Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
-
BUSINESS Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
-
BUSINESS ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
-
REGULATORY 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
-
ORGANIZATION Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
-
REGULATORY JMACCT Revamps Database of Clinical Trial Institutions; Details Now Available Online
February 27, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…